The COVID-19 outbreak is a great threat to public health worldwide. Lung injury is the main outcome of COVID-19 infection; however, damage can occur in other organs including the liver. Currently, limited data are available that link underlying liver injury with the severe SARS-CoV-2 infection. This review summarizes the available data on liver test abnormalities in COVID-19 patients; critically evaluates the possible causes of liver injury and provides recommendations for clinicians. In laboratory tests, serum levels of liver test markers notably transaminase, gamma-glutamyl transferase and total bilirubin were significantly higher in severe patients with COVID-19 infection. The use of certain drugs especially lopinavir and ritonavir showed an association with the progression of liver damage in severe cases. Available data suggest that liver injury in COVID-19 patients may result from direct effect by the virus, immune-mediated inflammation or drug-induced toxicity. Some studies demonstrated that COVID-19 patients with pre-existing liver disease are at higher risk for hospitalizations and mortality. Therefore, the impact of pre-existing liver disease on treatment and clinical outcomes of COVID-19 should be determined. Large-scale clinical studies are needed to identify the causes of liver injury in patients with COVID-19 infection.
【저자키워드】 COVID-19, SARS-CoV-2, Liver injury, liver enzymes, Liver disease, 【초록키워드】 Treatment, public health, Mortality, Hospitalization, Ritonavir, Infection, Toxicity, Laboratory tests, drug, progression, outcome, virus, Clinical outcome, COVID-19 outbreak, severe cases, Severe patient, liver, association, marker, Liver damage, clinical study, Injury, COVID-19 patient, Clinicians, available data, higher risk, total bilirubin, Serum level, abnormality, recommendation, severe SARS-CoV-2, identify, evaluate, provide, occur, demonstrated, significantly higher, cause, immune-mediated inflammation, other organ, patients with COVID-19, with COVID-19, 【제목키워드】 review, recent, relationship,